Arcadia Investment Management Corp MI Invests $843,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Arcadia Investment Management Corp MI acquired a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 6,935 shares of the biotechnology company’s stock, valued at approximately $843,000.

Several other large investors have also modified their holdings of SRPT. Handelsbanken Fonder AB raised its position in Sarepta Therapeutics by 7.1% during the fourth quarter. Handelsbanken Fonder AB now owns 25,515 shares of the biotechnology company’s stock valued at $3,102,000 after buying an additional 1,700 shares during the period. Peregrine Capital Management LLC grew its stake in Sarepta Therapeutics by 28.6% during the 4th quarter. Peregrine Capital Management LLC now owns 53,804 shares of the biotechnology company’s stock valued at $6,542,000 after acquiring an additional 11,965 shares in the last quarter. Atria Wealth Solutions Inc. increased its holdings in shares of Sarepta Therapeutics by 10.5% in the 4th quarter. Atria Wealth Solutions Inc. now owns 11,692 shares of the biotechnology company’s stock valued at $1,422,000 after purchasing an additional 1,108 shares during the period. CIBC Asset Management Inc lifted its position in shares of Sarepta Therapeutics by 5.1% in the fourth quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company’s stock worth $347,000 after purchasing an additional 139 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its position in shares of Sarepta Therapeutics by 5.6% in the fourth quarter. Principal Financial Group Inc. now owns 282,084 shares of the biotechnology company’s stock worth $34,299,000 after purchasing an additional 15,047 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares in the company, valued at $738,234. This trade represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $108.41 on Friday. The company has a market capitalization of $10.36 billion, a PE ratio of 86.73 and a beta of 0.75. Sarepta Therapeutics, Inc. has a one year low of $101.15 and a one year high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The company’s fifty day moving average price is $117.88 and its 200 day moving average price is $123.85.

Analysts Set New Price Targets

Several research analysts have weighed in on SRPT shares. Piper Sandler dropped their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $152.00 to $167.00 in a report on Thursday, November 7th. HC Wainwright reiterated a “sell” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, February 13th. Robert W. Baird reduced their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Finally, Evercore ISI dropped their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $176.77.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.